Predictors of Chemotherapy Induced Adverse Events in Pediatric Osteosarcoma Patients

Sanguanboonyaphong, Phitjira; Komvilaisak, Patcharee; Suwannaying, Kunanya; Yoodee, Jukapun; Saeteaw, Manit; Chanthawong, Suthan; Subongkot, Suphat

doi:10.31557/apjcp.2022.23.1.93

Cited by 7 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy-induced unfavorable occurrences can exert a noteworthy influence on the quality of life of individuals afflicted with osteosarcoma. Negative occurrences such as nausea and vomiting, hepatotoxicity, anemia, neutropenia, and thrombocytopenia were discovered to be widespread in pediatric osteosarcoma patients enduring chemotherapy [13]. Factors linked with chemotherapy-induced liver toxicity comprised of increased chemotherapy quantities, elevated plasma methotrexate levels, and a more gradual pre-hydration velocity [31].…”

Section: Discussionmentioning

confidence: 99%

“…However, it is difficult to decide which is superior amidst these combinations while multiple studies revealed different efficacy outcomes. Additionally, multi-drug chemotherapy toxicity could affect the patients quality of life [13]. Hereby, we carried out a meta-analysis approach to assess the efficacy and safety of a specific combination of MAP regimen compared to other regimens as chemotherapy protocols for the treatment of osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

Ismail,

Wiratnaya,

Raditya

2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Several studies of multi-drug regimens for osteosarcoma have shown different efficacies and are still controversial. Meanwhile, chemotherapy options have remained largely unchanged over a couple of decades. This study is designed to ascertain the outcome and safety of Methotrexate, Doxorubicin, and Cisplatin regimen for chemotherapy in osteosarcoma patients through the utilization of meta-analysis. Methods: We interrogated trials that compared the MAP regimen with other regimens as chemotherapy for osteosarcoma from several databases encompassing PubMed, Science Direct, and grey literature (Google Scholar) until December 2022. The analyzed outcomes including Event-Free Survival (EFS), Overall Survival (OS), Tumor Necrosis (TN) rate, and Adverse Event (AE) were then analyzed using RevMan 5.4 software in fixed or random effect models. Results: Our meta-analysis comprised 8 prospective articles that evaluated a cumulative number of 2920 OS patients. The analysis results indicated no meaningful difference in 5-year EFS (OR=0.99, 95% CI=0.77-1.27, [P = 0.91]) and neoadjuvant chemotherapy response (TN) (OR=0.76, 95% CI=0.49-1.17, [P = 0.22]) between the MAP and control groups. Furthermore, 5-year OS analysis revealed a significant association in the control group (OR=0.82, 95% CI=0.68-0.99, [P = 0.04]). However, the control group was associated with statistically meaningful AE compared to the MAP group, particularly in thrombocytopenia (OR=0.46, 95% CI=0.23-0.90, [P = 0.02]) and fever (OR=0.34, 95% CI=0.26-0.46, [P < 0.00001]). Conclusion: The present meta-analysis showed that the MAP regimen remains preferable in treating osteosarcoma patients despite no significant outcome compared to the other regimens considering the less frequent AE in the MAP regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

Ismail,

Wiratnaya,

Raditya

2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Myelosuppression is a common potentially life‐threatening adverse effect (AE) of chemotherapy in childhood cancers 1 . Chemotherapy‐induced neutropenia (CIN) is dose‐dependent and occurs in 26%–45% of treated individuals 2,3 . CIN is associated with high morbidity and mortality in children 3 .…”

Section: Introductionmentioning

confidence: 99%

“… 1 Chemotherapy‐induced neutropenia (CIN) is dose‐dependent and occurs in 26%–45% of treated individuals. 2 , 3 CIN is associated with high morbidity and mortality in children. 3 Moreover, CIN can lead to chemotherapy interruption and dose adjustments, affecting the treatment outcomes.…”

Section: Introductionmentioning

confidence: 99%

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis

Huang,

Lu,

Wang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF) can be used in pediatric patients. This study assessed the safety and efficacy of PEG‐rhG‐CSF as a primary prophylactic drug against neutropenia after chemotherapy in pediatric patients with solid tumors or non‐Hodgkin lymphoma (NHL). Patients and Methods This phase II study (between October 2020 and March 2022) enrolled pediatric patients with solid tumors or NHL treated with high‐intensity chemotherapy and with grade ≥3 myelosuppression for at least 14 days during chemotherapy. Prophylactic PEG‐rhG‐CSF was given at 100 μg/kg body weight (maximum total dosage of 6 mg) once 24–48 h following chemotherapy for two cycles. The primary endpoint was the incidence of PEG‐rhG‐CSF‐related adverse events (AEs). The key secondary endpoints were the rates of grade 3/4 neutropenia and febrile neutropenia (FN). Results This study included 160 pediatric patients with a median age of 6.22 (0.29, 18.00) years. Fifty‐eight patients (36.25%) were diagnosed with sarcoma. AEs potentially related to PEG‐rhG‐CSF included bone pain (n = 32), fatigue (n = 21), pain at the injection site (n = 21), and myalgia (n = 20). The rates of grade 3/4 neutropenia and FN during treatment were 57.28% and 29.45%, respectively. Conclusion PEG‐rhG‐CSF is well tolerated and effective in pediatric patients with solid tumors or NHL. These findings should be substantiated with further trials. Clinical Trial Registration ClinicalTrials.gov identifier: NCT04547829.

show abstract

Design, synthesis and anti-osteosarcoma activity study of novel pyrido[2,3-d]pyrimidine derivatives by inhibiting DKK1-Wnt/β-catenin pathway

Shen,

Xie,

Wang

et al. 2023

Bioorganic Chemistry

View full text Add to dashboard Cite

Predictors of Chemotherapy Induced Adverse Events in Pediatric Osteosarcoma Patients

Abstract: Objective: To investigate the prevalence of chemotherapy-induced adverse events and the associated risk factors in pediatric patients with osteosarcoma. Methods: This retrospective cross-sectional study enrolled 90 pediatric osteosarcoma patients (with 1,017 chemotherapy cycles) treated at

Cited by 7 publications

References 42 publications

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis

Design, synthesis and anti-osteosarcoma activity study of novel pyrido[2,3-d]pyrimidine derivatives by inhibiting DKK1-Wnt/β-catenin pathway

Contact Info

Product

Resources

About